NCT03340506 2026-04-20Dabrafenib and/or Trametinib Rollover StudyNovartisPhase 4 Recruiting100 enrolled
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT02974725 2025-04-13A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaNovartisPhase 1 Terminated241 enrolled